What Galectin Therapeutics Inc does.

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic

steatohepatitis, or NASH) with cirrhosis and certain cancer indications. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources.

Revenue and profit, by fiscal year.

More on GALT.

• Galectin Therapeutics Inc summary
• Galectin Therapeutics Inc financial statements
• Galectin Therapeutics Inc key metrics
• Galectin Therapeutics Inc health scores and style box
• Galectin Therapeutics Inc earnings
• Galectin Therapeutics Inc dividends
• Galectin Therapeutics Inc valuation
• Galectin Therapeutics Inc ownership and insiders
• Galectin Therapeutics Inc peers

Figures from Galectin Therapeutics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.